Inspire Advisors LLC Buys 999 Shares of CRISPR Therapeutics AG $CRSP

Inspire Advisors LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,474 shares of the company’s stock after buying an additional 999 shares during the quarter. Inspire Advisors LLC’s holdings in CRISPR Therapeutics were worth $704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after purchasing an additional 1,192,336 shares in the last quarter. IVC Wealth Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at $225,000. Koss Olinger Consulting LLC lifted its position in CRISPR Therapeutics by 29.8% in the second quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock worth $2,052,000 after purchasing an additional 9,685 shares during the period. Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock worth $60,223,000 after buying an additional 33,711 shares in the last quarter. Finally, Slow Capital Inc. boosted its stake in CRISPR Therapeutics by 15.6% during the second quarter. Slow Capital Inc. now owns 75,396 shares of the company’s stock worth $3,667,000 after buying an additional 10,152 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Barclays increased their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Needham & Company LLC lowered their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Finally, Wedbush lowered their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $67.84.

CRISPR Therapeutics Stock Down 3.3%

Shares of CRISPR Therapeutics stock opened at $53.47 on Wednesday. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48. The stock has a market capitalization of $5.10 billion, a P/E ratio of -9.57 and a beta of 1.89. The company has a 50-day simple moving average of $62.96 and a 200 day simple moving average of $53.98.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 50,895 shares of the firm’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the completion of the sale, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This trade represents a 16.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the transaction, the general counsel owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 56,213 shares of company stock worth $3,810,458. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.